Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system

Hepatology

Volumn 64, Issue 6, 2016, Pages 1900-1910

  Wang, Richard Y ^a   Bare, Patricia ^a,b   De Giorgi, Valeria ^a   Matsuura, Kentaro ^a,c   Salam, Kazi Abdus ^a,d   Grandinetti, Teresa ^a   Schechterly, Cathy ^a   Alter, Harvey J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d UNIVERSITY OF RAJSHAHI   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD81 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT RECEPTOR;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; BURKITT LYMPHOMA; CHRONIC HEPATITIS C; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAJI CELL LINE; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS PARTICLE; CELL CULTURE; HEPACIVIRUS; IMMUNOLOGY; MONONUCLEAR CELL; PHYSIOLOGY; VIROLOGY;

ANTIGENS, CD19; B-LYMPHOCYTES; CELLS, CULTURED; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, COMPLEMENT;

EID: 84995803010     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28842     Document Type: Article

References (48)

1. Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: a global view. World J Hepatol 2015;7:2676–2680.
2. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006;44:15–22.
3. Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol 2015;7:327–343.
4. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009;76:818–824.
5. Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus 2015;24:469–482.
6. MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 2009;49:1431–1441.
7. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008;134:812–822.
8. Pham TN, Michalak TI. Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008;14:2789–2793.
9. Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007;39(Suppl. 1):S38–S45.
10. Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, et al. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 2013;57:483–491.
11. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009;49:665–675.
12. Boisvert J, He XS, Cheung R, Keeffe EB, Wright T, Greenberg HB. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J Infect Dis 2001;184:827–835.
13. Zehender G, Meroni L, De Maddalena C, Varchetta S, Monti G, Galli M. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. J Infect Dis 1997;176:1209–1214.
14. Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008;82:3555–3560.
15. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007;46:1722–1731.
16. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008;48:1843–1850.
17. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005;102:18544–18549.
18. Stamataki Z, Shannon-Lowe C, Shaw J, Mutimer D, Rickinson AB, Gordon J, et al. Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 2009;113:585–593.
19. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127–149.
20. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992;256:105–107.
21. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway—its role in innate immunity and evolution. Immunol Rev 2004;198:185–202.
22. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785–797.
23. Stoermer KA, Morrison TE. Complement and viral pathogenesis. Virology 2011;411:362–373.
24. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 2008;26:3046–3054.
25. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, et al. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest 2013;123:2218–2230.
26. + T cells leads to impaired activation of Lck and Akt. J Virol 2004;78:6409–6419.
27. Morgan BP. The complement system: an overview. Methods Mol Biol 2000;150:1–13.
28. Rickert RC. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr Opin Immunol 2005;17:237–243.
29. Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med 2000;192:637–646.
30. Lee MS, Jones T, Song DY, Jang JH, Jung JU, Gao SJ. Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection. PLoS Pathog 2014;10:e1004412.
31. Mason CP, Tarr AW. Human lectins and their roles in viral infections. Molecules 2015;20:2229–2271.
32. Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011;17:195–199.
33. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, et al. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 2010;184:359–368.
34. Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH, Arnold JN, et al. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 2010;1:664–674.
35. Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP, Krarup A, et al. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. J Innate Immun 2014;6:676–684.
36. Kim H, Meyer K, Di Bisceglie AM, Ray R. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 2013;87:5858–5867.
37. Amet T, Ghabril M, Chalasani N, Byrd D, Hu N, Grantham A, et al. CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology 2012;55:354–363.
38. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, et al. Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J Virol 2013;87:7902–7910.
39. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59:169–177.
40. Vannata B, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2014;2014:590–598.
41. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004;101:4262–4267.
42. Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma 2003;44:1113–1120.
43. Carbonari M, Caprini E, Tedesco T, Mazzetta F, Tocco V, Casato M, et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005;174:6532–6539.
44. Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001;97:1023–1026.
45. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001;159:253–261.
46. Ng PP, Kuo CC, Wang S, Einav S, Arcaini L, Paulli M, et al. B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood 2014;123:1512–1515.
47. Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013;23:410–421.
48. Pierce SK. Lipid rafts and B-cell activation. Nat Rev Immunol 2002;2:96–105.